Form 8-K - Current report:
SEC Accession No. 0001437749-24-029206
Filing Date
2024-09-16
Accepted
2024-09-16 09:01:05
Documents
14
Period of Report
2024-09-12
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbyi20240913_8k.htm   iXBRL 8-K 35535
  Complete submission text file 0001437749-24-029206.txt   173010

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20240912.xsd EX-101.SCH 3409
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbyi-20240912_def.xml EX-101.DEF 11807
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20240912_lab.xml EX-101.LAB 15858
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20240912_pre.xml EX-101.PRE 12022
16 EXTRACTED XBRL INSTANCE DOCUMENT pbyi20240913_8k_htm.xml XML 2971
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

EIN.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 241299481
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)